Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEMA‐ERIC and US study
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Medicine"
DOI: 10.1002/cam4.3470
Abstract: Limited information is available on the efficacy of front‐line bendamustine and rituximab (BR) in chronic lymphocytic leukemia (CLL) with reduced renal function or coexisting conditions. We therefore analyzed a cohort of real‐world patients and performed… read more here.
Keywords: real world; ibrutinib; lymphocytic leukemia; bendamustine rituximab ... See more keywords
Maintenance rituximab or observation after frontline treatment with bendamustine‐rituximab for follicular lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Haematology"
DOI: 10.1111/bjh.15720
Abstract: Bendamustine (B) with rituximab (R) is a standard frontline treatment for medically fit follicular lymphoma (FL) patients. The safety and efficacy of maintenance rituximab (MR) after BR induction has not been formally compared to observation… read more here.
Keywords: rituximab; maintenance rituximab; maintenance; follicular lymphoma ... See more keywords
Risk‐adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real‐world report on 141 consecutive Swedish patients
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Haematology"
DOI: 10.1111/bjh.17032
Abstract: Bendamustine + rituximab (BR) is the current first‐line standard‐of‐care for chronic lymphocytic leukaemia (CLL) in fit patients aged 66–70 years, whereas chlorambucil + CD20 antibody is recommended in older patients with co‐morbidities. This retrospective real‐world… read more here.
Keywords: real world; line; lymphocytic leukaemia; bendamustine rituximab ... See more keywords
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006844
Abstract: Key Points Bendamustine with rituximab is a highly effective frontline therapy in extranodal marginal zone lymphoma across all extranodal sites. Bendamustine with rituximab overcomes known poor prognosis features in extranodal marginal zone lymphoma. read more here.
Keywords: international analysis; bendamustine rituximab; extranodal marginal; marginal zone ... See more keywords
Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial
Sign Up to like & getrecommendations! Published in 2019 at "Health and Quality of Life Outcomes"
DOI: 10.1186/s12955-019-1232-8
Abstract: BackgroundIn a phase 3 randomized, double-blind, placebo-controlled trial, treatment with idelalisib, a phosphoinositol-3 kinase δ inhibitor, + bendamustine/rituximab improved progression-free survival (PFS) and overall survival (OS) in adult patients with relapsed/refractory chronic lymphocytic leukemia (R/R… read more here.
Keywords: bendamustine rituximab; placebo; idelalisib; quality life ... See more keywords